GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (AMEX:LCTX) » Definitions » Future 3-5Y Total Revenue Growth Rate

LCTX (Lineage Cell Therapeutics) Future 3-5Y Total Revenue Growth Rate : 88.10 (As of Mar. 31, 2025)


View and export this data going back to 1992. Start your Free Trial

What is Lineage Cell Therapeutics Future 3-5Y Total Revenue Growth Rate?

Future 3-5Y Total Revenue Growth Rate is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate is 88.10.


Competitive Comparison of Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate

For the Biotechnology subindustry, Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate, along with its competitors' market caps and Future 3-5Y Total Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate falls into.


;
;

Lineage Cell Therapeutics  (AMEX:LCTX) Future 3-5Y Total Revenue Growth Rate Explanation

Future 3-5Y Total Revenue Growth Rate is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.


Lineage Cell Therapeutics Future 3-5Y Total Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Future 3-5Y Total Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Jill Ann Howe officer: Chief Financial Officer C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Samuel George A. Iii officer: General Counsel/Secretary C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Brian M Culley director, officer: President and CEO 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Don M Bailey director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Dipti Amin director C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Gary S. Hogge officer: SVP,Clinical & Medical Affairs 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kevin Leon Cook officer: Chief Financial Officer C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Alexandra Hernandez officer: Sr Director Finance/Controller C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Brandi Roberts officer: CFO & SVP, Finance 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Edward Wirth officer: Chief Medical Officer C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142